Preliminary Exploration of Clinical Efficacy and Pharmacological Mechanism of Modified Danggui-Shaoyao San in the Treatment of Depression in Patients with Chronic Kidney Disease
DOI: https://doi.org/10.2147/DDDT.S387677
2022-11-17
Abstract:Mengdi Xia, 1, 2, &ast Na Ai, 3, &ast Junjie Pang 4 1 Department of Nephrology, the Second Clinical Medical Institution of North, Sichuan Medical College (Nanchong Central Hospital), Nanchong, 637000, People's Republic of China; 2 Department of Nephrology and Medical Intensive Care, Charite ́-Universtitätsmedizin Berlin, Berlin, 12203, Germany; 3 Department of General Internal Medicine, the Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China; 4 Hemodialysis Center, Santai County Traditional Chinese Medicine Hospital, Mianyang, 621100, People's Republic of China &astThese authors contributed equally to this work Correspondence: Mengdi Xia; Junjie Pang, Email ; Background: Depression in Chronic Kidney Disease (CKD) seriously affects the prognosis of patients and Modified Danggui-Shaoyao-San (MDSS) is based on the traditional Chinese formula Danggui-Shaoyao-San (DSS) for the treatment of depression, which is further optimized. The aim of this study was to evaluate the clinical efficacy and safety of MDSS for the treatment of depression in CKD, and to explain the molecular mechanism of MDSS for the treatment of depression in CKD through pharmacology and molecular docking. Methods: 62 patients were randomly divided into treatment group (treated with MDSS) and control group (treated with placebo) and assessed by Hamilton Depression Scale, and the primary outcome was to evaluate the efficacy of MDSS in improving depressive symptoms and the effect on liver and kidney function, electrolytes. In addition, we identified the core compounds and potential targets of MDSS through the TCMSP database. The GeneCards, OMIM and Disgenet databases were then used to identify molecular targets for CKD and depression. The target protein–protein interaction network was built using STRING database. Core targets were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Molecular docking was used to verify the relationship between core active compounds and proteins. Results: Clinical results showed that CKD patients in the MDSS group had significantly improved depressive status with no significant adverse effects. By network pharmacology analysis, we found that the compound-target network mainly contained 47 compounds and 69 corresponding targets. 844 terms were analyzed by GO enrichment, and 254 signaling pathways in KEGG. Molecular docking showed that the top active compounds had high affinity with four targets. Conclusion: We preliminarily investigated the efficacy of MDSS in the treatment of depression in CKD and revealed the characteristics of multiple compounds and multiple targets in MDSS. Keywords: Modified Danggui-Shaoyao San, depression, chronic kidney disease, clinical efficacy, network pharmacology Depression is a leading contributor to the overall global burden of disease, 1 and as a common comorbidity in patients with chronic kidney disease (CKD), depression is five times more prevalent in patients with CKD than in the general population. 2 Also, it exacerbates clinical symptoms associated with CKD, decreases the quality of life and medication adherence of patients, 3 as well as significantly increases cardiovascular events and deaths. 4 However, the current major approach to the therapy of depression in comorbid CKD is mostly western pharmacotherapy, and these medications are often associated with serious hepatic and renal toxicity. 5 On the one hand, the renal dysfunction of CKD patients exacerbates this adverse effect; on the other hand, physicians may fear the adverse effects of these drugs on the renal function of CKD patients and thus reduce the dose of antidepressants or abandon antidepressant treatment for CKD patients. 6 This ultimately limits the treatment strategy for depression in CKD patients. Danggui-Shaoyao-San (DSS) originated from the earliest Chinese monograph on the diagnosis and treatment of miscellaneous diseases, "Synopsis of Golden Chamber", and is a traditional compound Chinese medicinal preparation composed mainly of Angelica and Paeoniae, which has been used since ancient times to nourish the heart and calm the mind, and modern studies have confirmed that this formula can significantly improve depression. 7,8 In recent years, famous Sichuan traditional Chinese medicine practitioners combined the clinical herbal characteristics and clinical medication experience to further improve the basis DSS of adding diuretic and kidney-nourishing herbs such as Rehmanniae, Poria and Amomum, etc., which nourish the liver and kidney, to -Abstract Truncated-